Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany

[featured_image]
  • Version
  • Download 655
  • Dateigrösse 0.00 KB
  • Datei-Anzahl 1
  • Erstellungsdatum 1. January 2019
  • Zuletzt aktualisiert 13. July 2023

Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany

Attached Files

DateiAktion
s40258-019-00523-1Download